On April 15, 2016 Incyte Corporation (Nasdaq: INCY) reported that will highlight the productivity of its drug discovery and development organization and aspects of its development portfolio at an investor event on Sunday, April 17, 2016 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 in New Orleans, Louisiana (Press release, Incyte, APR 15, 2016, View Source [SID:1234510879]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will include a discussion of Incyte’s second-generation PI3Kδ inhibitor, INCB50465; the Company’s immuno-oncology portfolio, including its anti-GITR antibody, INCAGN1876, anti-OX40 antibody, INCAGN1949, and emerging data with its small molecule BRD inhibitor, INCB54329; as well as its targeted epigenetic therapies, including a novel LSD1 inhibitor entering Phase 1 development, INCB59872.
"Incyte operates with the conviction that investment in basic research can translate into innovative therapies that can address important unmet medical needs. To that end, we are pleased to be able to highlight such a broad collection of abstracts from our emerging development portfolio at this year’s AACR (Free AACR Whitepaper) Annual Meeting," stated Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. "The research team’s productivity is a result of the quality of our scientific organization and the efficiency of our R&D model."
As part of its succession plan, Incyte also announced that after almost 13 years at the Company, Dr. Richard Levy, Chief Drug Development Officer, is retiring effective April 30, 2016. Dr. Steven Stein, Incyte’s Chief Medical Officer, will now assume all of Dr. Levy’s responsibilities. Dr. Levy was instrumental in building the broad and diverse portfolio Incyte has today, and developing Jakafi (ruxolitinib), the Company’s proprietary JAK 1/JAK 2 inhibitor.